TY - JOUR
T1 - Disposition and metabolism of NY-198 II. Hplc and bioassay studies of absorption and excretion in the dog
AU - Okezaki, Eiichi
AU - Makino, Eiichi
AU - Ohmichi, Kohichi
AU - Nagata, Osamu
AU - Yamada, Takehisa
AU - Takahashi, Kazuyo
AU - Terasaki, Testuya
AU - Tsuji, Akira
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1988
Y1 - 1988
N2 - We investigated serum levels and urinary excretion of NY-198 using HPLC and bioassay methods after oral administration to dogs at a dose of 20mg/kg. Average serum levels of NY-198 reached a peak concentration of 8.95 μg/ml at 1 h after oral dosing, and then declined with a half-life of 7.1 h. NY-198 was excreted rapidly in urine after oral dosing, and the peak concentration was obtained in 6-12 hurine. A high urinary concentration of more than 50 μg/ml was maintained up to 48 h. Urinary excretion was 40.3% at 24 h and 51.8% at 72 h. Concentrations of NY-198 in serum and urine were measured by both HPLC and bioassay, and good correlation between the two assays was obtained. These results suggest that active metabolites possesing antimicrobial activity are not present in serum or urine after oral administration of NY-198.
AB - We investigated serum levels and urinary excretion of NY-198 using HPLC and bioassay methods after oral administration to dogs at a dose of 20mg/kg. Average serum levels of NY-198 reached a peak concentration of 8.95 μg/ml at 1 h after oral dosing, and then declined with a half-life of 7.1 h. NY-198 was excreted rapidly in urine after oral dosing, and the peak concentration was obtained in 6-12 hurine. A high urinary concentration of more than 50 μg/ml was maintained up to 48 h. Urinary excretion was 40.3% at 24 h and 51.8% at 72 h. Concentrations of NY-198 in serum and urine were measured by both HPLC and bioassay, and good correlation between the two assays was obtained. These results suggest that active metabolites possesing antimicrobial activity are not present in serum or urine after oral administration of NY-198.
UR - http://www.scopus.com/inward/record.url?scp=85004204778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004204778&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.36.Supplement2-Base_138
DO - 10.11250/chemotherapy1953.36.Supplement2-Base_138
M3 - Article
AN - SCOPUS:85004204778
SN - 0009-3165
VL - 36
SP - 138
EP - 143
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
ER -
